Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells 369,800 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ra Capital Management, L.P. sold 369,800 shares of the company’s stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $0.37, for a total transaction of $136,826.00. Following the completion of the transaction, the insider owned 381,717 shares in the company, valued at approximately $141,235.29. This represents a 49.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Thursday, June 11th, Ra Capital Management, L.P. sold 262,503 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.38, for a total value of $99,751.14.
• On Wednesday, June 10th, Ra Capital Management, L.P. sold 45,923 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.37, for a total value of $16,991.51.
• On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total value of $64,736.64.
• On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total value of $58,618.30.
• On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.71, for a total value of $267,333.46.

Werewolf Therapeutics Stock Up 8.0%

NASDAQ HOWL traded up $0.03 during midday trading on Thursday, hitting $0.39. The company had a trading volume of 805,388 shares, compared to its average volume of 538,108. The stock has a market cap of $19.16 million, a price-to-earnings ratio of -0.32 and a beta of 0.29. The firm has a fifty day simple moving average of $0.67 and a two-hundred day simple moving average of $0.72. Werewolf Therapeutics, Inc. has a fifty-two week low of $0.36 and a fifty-two week high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.04. As a group, equities analysts predict that Werewolf Therapeutics, Inc. will post -1.08 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have issued reports on HOWL shares. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Wall Street Zen downgraded shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Two analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $3.75.

Institutional Trading of Werewolf Therapeutics

A number of large investors have recently bought and sold shares of the stock. Regal Investment Advisors LLC boosted its holdings in shares of Werewolf Therapeutics by 93.3% in the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after acquiring an additional 25,389 shares in the last quarter. Vontobel Holding Ltd. boosted its holdings in shares of Werewolf Therapeutics by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after acquiring an additional 24,003 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Werewolf Therapeutics by 48.6% in the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after acquiring an additional 221,766 shares in the last quarter. Susquehanna International Group LLP boosted its holdings in shares of Werewolf Therapeutics by 16.9% in the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after acquiring an additional 13,439 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new position in shares of Werewolf Therapeutics in the 3rd quarter worth approximately $304,000. 64.84% of the stock is currently owned by institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.